GENINCODE PLC (GENI) — Interim results presentation

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the GENINCODE Interim Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Simply type in your questions at any time and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review your questions submitted today, and we'll publish those responses where it's appropriate to do so. Before we begin, we'd like to submit the following poll. And if you'd be so kind to give that your attention, I'm sure the company would be most grateful. I'd now like to hand over to CEO, Matthew Walls. Good afternoon. Good afternoon, Mark, and good afternoon, everyone online. Thanks for attending today. Hopefully, you can see the presentation of the interim results. So we've been here today, myself and Paul Fulgi, who's with me, CFO, presenting to investors in in the city. It's, pouring down outside, so pleased to be inside and not dashing from meeting to meeting. Anyway, we'll skip through the first few slides, but, just to give a quick summary as we go. We'll hit on most of the points that we typically report on, and then we'll finish up on summary and outlook. Board, no changes. Again, I won't go spend too much time on on the GENICODE summary, but you you get a little bit of a summary as to where where we are in terms of background, how we formed as a company, intellectual property, the reason for why we're focused on cardiovascular disease. And, really, the the essence of today is around the interim results that we're presenting. So I'm gonna walk through these, and we'll...